4-异氰酰苯基硼酸频哪醇酯 | 380430-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-异氰酰苯基硼酸频哪醇酯
• 中文别名: 4-异氰基苯硼酸频哪酯
• 英文名称: 2-(4-isocyanatophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• 英文别名: (4-isocyanatophenyl)boronic acid, pinacol ester
• CAS: 380430-64-8
• 化学式: C₁₃H₁₆BNO₃
• mdl: MFCD03411942
• 分子量: 245.086
• InChiKey: RHKRIDVZGAXYQE-UHFFFAOYSA-N

物化性质

• 熔点：
  162-168
• 沸点：
  100-105°C 2mm

计算性质

• 辛醇/水分配系数(LogP)：
  3.75
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  T,C
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 2206
• 海关编码：
  2931900090
• 安全说明：
  S26,S28,S36/37/39

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Isocyanatophenylboronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H311: Toxic in contact with skin
H332: Harmful if inhaled
Causes skin irritation
H315:
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P361: Remove/Take off immediately all contaminated clothing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Isocyanatophenylboronic acid, pinacol ester
CAS number: 380430-64-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H16BNO3
Molecular weight: 245.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-异氰酰苯基硼酸频哪醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 利尼伐尼
  参考文献：
  名称：

  Discovery of N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

  摘要：

  In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N'-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.

  DOI：

  10.1021/jm061280h
• 作为产物：
  描述：

  三光气 、 4-氨基苯硼酸频哪醇酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 以61%的产率得到4-异氰酰苯基硼酸频哪醇酯
  参考文献：
  名称：

  通过片段优化方法发现的 RET 肺癌癌蛋白的吡唑啉酮抑制剂

  摘要：

  基于片段的药物发现方法用于吡唑核苷片段库，以发现靶向 RET（转染期间重新排列）癌蛋白的新分子，该蛋白是约 2% 的非小细胞肺癌的驱动癌蛋白。针对 RET 激酶和 LC-2/ad（RET 驱动）、KM-12（TRKA 驱动匹配对照）和 A549（细胞毒性对照）细胞筛选片段文库，以鉴定可抑制 RET 驱动生长的选择性支架。在生化测定中发现未取代的吡唑核苷片段对 RET 有活性，但降低了非 RET 驱动的细胞系中的细胞活力 (EC 50= 1 和 3 μM，分别）。为了提高 RET 的选择性，在 RET 活性位点中模拟了吡唑核苷，并确定了两个结构域，用吡唑核苷片段衍生物进行探测以提高 RET 亲和力。合并每个结构域的支架以生成新型先导化合物8 p，它对 RET 癌蛋白表现出更高的活性和选择性（A549 EC 50 =5.92 μM，LC-2/ad EC 50 =0.016 μM，RET IC 50

  DOI：

  10.1002/cmdc.202100013

文献信息

• SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160326125A1

  公开（公告）日：2016-11-10

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments.

  本发明提供了规范中定义的Formula (I)的化合物以及包含任何此类新化合物的组合物。这些化合物是内皮酶抑制剂，可用作药物。
• 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Bursavich Matthew Gregory

  公开号：US20100015141A1

  公开（公告）日：2010-01-21

  The invention relates to 4,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds, including 4-phenoxy-6-aryl-1H-pyrazolo[3,4-d]pyrimidine and N-aryl-6-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  本发明涉及4,6-二取代-1H-吡唑[3,4-d]嘧啶-4-胺化合物，包括4-苯氧基-6-芳基-1H-吡唑[3,4-d]嘧啶和N-芳基-6-芳基-1H-吡唑[3,4-d]嘧啶-4-胺的化合物，其化学式为I： 或其药用可接受盐，其中组成变量如本文所述，包含该化合物的组合物，以及制造和使用这些化合物的方法。
• [EN] MAP4K4 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K4
  申请人：IMPERIAL INNOVATIONS LTD

  公开号：WO2019073253A1

  公开（公告）日：2019-04-18

  This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

  这项发明涉及含有吡咯吡嘧啶的化合物，这些化合物可能作为丝裂原活化蛋白激酶激酶激酶激酶-4（MAP4K4）的抑制剂而有用。该发明还涉及利用这些含有吡咯吡嘧啶的化合物，例如在治疗方法中的使用。还提供了生产本发明化合物的方法以及它们的使用方法。具体而言，本发明涉及式（I）的化合物。
• (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Chen Zecheng

  公开号：US20100003250A1

  公开（公告）日：2010-01-07

  The invention relates to 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及Formula I的2-芳基-7H-吡咯并[2,3-d]嘧啶-4-基)吗啉化合物或其药用可接受的盐，其中组分变量如本文所定义，包括这些化合物的组合物，以及制备和使用这些化合物的方法。
• [EN] PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES<br/>[FR] COMPOSÉS DE PYRIMIDINE, LEUR UTILISATION COMME INHIBITEURS DE LA MTOR KINASE ET DE LA PI3 KINASE ET LEURS PROCÉDÉS DE SYNTHÈSE
  申请人：WYETH LLC

  公开号：WO2010120998A1

  公开（公告）日：2010-10-21

  The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及公式I的嘧啶化合物或其药用可接受盐，其中组成变量如本文所定义，包括这些化合物的组合物，以及制备和使用这些化合物的方法。